These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27463224)

  • 1. Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus.
    Boyington JC; Joyce MG; Sastry M; Stewart-Jones GB; Chen M; Kong WP; Ngwuta JO; Thomas PV; Tsybovsky Y; Yang Y; Zhang B; Chen L; Druz A; Georgiev IS; Ko K; Zhou T; Mascola JR; Graham BS; Kwong PD
    PLoS One; 2016; 11(7):e0159709. PubMed ID: 27463224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus.
    Sastry M; Zhang B; Chen M; Joyce MG; Kong WP; Chuang GY; Ko K; Kumar A; Silacci C; Thom M; Salazar AM; Corti D; Lanzavecchia A; Taylor G; Mascola JR; Graham BS; Kwong PD
    PLoS One; 2017; 12(10):e0186854. PubMed ID: 29073183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus.
    Stewart-Jones GB; Thomas PV; Chen M; Druz A; Joyce MG; Kong WP; Sastry M; Soto C; Yang Y; Zhang B; Chen L; Chuang GY; Georgiev IS; McLellan JS; Srivatsan S; Zhou T; Baxa U; Mascola JR; Graham BS; Kwong PD
    PLoS One; 2015; 10(6):e0128779. PubMed ID: 26098893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
    Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
    McGinnes Cullen L; Schmidt MR; Morrison TG
    J Virol; 2019 May; 93(9):. PubMed ID: 30760576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.
    Kwon YM; Lee Y; Kim KH; Jung YJ; Li Z; Jeeva S; Lee S; Moore ML; Kang SM
    Vaccine; 2019 Oct; 37(44):6656-6664. PubMed ID: 31542260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.
    Palomo C; Mas V; Thom M; Vázquez M; Cano O; Terrón MC; Luque D; Taylor G; Melero JA
    J Virol; 2016 Jun; 90(11):5485-5498. PubMed ID: 27009962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Trinité B; Durr E; Pons-Grífols A; O'Donnell G; Aguilar-Gurrieri C; Rodriguez S; Urrea V; Tarrés F; Mane J; Ortiz R; Rovirosa C; Carrillo J; Clotet B; Zhang L; Blanco J
    Vaccine; 2024 May; 42(15):3474-3485. PubMed ID: 38641492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
    Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus.
    Marcandalli J; Fiala B; Ols S; Perotti M; de van der Schueren W; Snijder J; Hodge E; Benhaim M; Ravichandran R; Carter L; Sheffler W; Brunner L; Lawrenz M; Dubois P; Lanzavecchia A; Sallusto F; Lee KK; Veesler D; Correnti CE; Stewart LJ; Baker D; Loré K; Perez L; King NP
    Cell; 2019 Mar; 176(6):1420-1431.e17. PubMed ID: 30849373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
    Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
    PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
    Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
    PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.
    Joyce MG; Zhang B; Ou L; Chen M; Chuang GY; Druz A; Kong WP; Lai YT; Rundlet EJ; Tsybovsky Y; Yang Y; Georgiev IS; Guttman M; Lees CR; Pancera M; Sastry M; Soto C; Stewart-Jones GBE; Thomas PV; Van Galen JG; Baxa U; Lee KK; Mascola JR; Graham BS; Kwong PD
    Nat Struct Mol Biol; 2016 Sep; 23(9):811-820. PubMed ID: 27478931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
    Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.